PwC and BIOTECanada invite Canada's Life Sciences
and Biotechnology sectors to participate in the fourth Canadian
Life Sciences Forecast.
The leading edge survey will gauge challenges and issues facing
the Life Sciences and Biotechnology industry. The survey's
results will be released in the Canadian Life Sciences Forecast
2013, in January 2013.
The report will provide a unique perspective on current issues,
forecasted trends and implications for the Canadian Life Sciences
and Biotechnology industry and will draw on survey responses from
Canadian executives and stakeholders. If you are a member of the
Life Sciences and Biotechnology industry, PwC and BIOTECanada
invite you to participate in this important senior executive
survey. The project's national launch will provide the results
to the media and general public. All individual responses are
completely confidential and will not be disclosed to any third
party. Only aggregated data will be reported.
To participate in this year's survey,
New mobile information technologies, combined with innovative
business models, offer consumers the promise of greater control
over their health, more choice, better access and a decrease in
We call this new paradigm intelligent healthcare, and it is
primed for significant global growth, with benefits such as:
Apps that act as a "clinician in a
box"—using sensors, algorithms and artificial
intelligence designed to simulate the advice of a clinician.
Empowering patients to self-help, and healthier behaviours,
while helping transform healthcare into a more productive
Tools offering constant expert clinical advice and support,
particularly for chronic diseases which require continual
Download the September issue of mHealth Insights to find out how
developers of "intelligent healthcare apps" can navigate
the regulatory requirements, ensure clinical efficacy, determine
payment structures—and leverage the abundant
opportunities available in this area of growing market
Health care companies are finding their own moments of truth
where they engage in new thinking about their customers. Whether
these moments are prompted by inspiration from other industries,
competition, health reform, consumer demands or the bottom line,
agile companies are changing the way they get to know their
customers, moving beyond basic transactions and embracing their
patients and members as consumers and customers.
US venture capital funding for the life sciences sector, The
MoneyTree life sciences sector includes the biotechnology and
medical device and equipment industries. Investments in these
industries fell 39% in dollars and 22% in number of deals during
the second quarter of 2012 from the same quarter of last year,
according to the MoneyTreeTM Report from
PricewaterhouseCoopers (PwC) LLP and the National Venture Capital
Association (NVCA) based on data provided by Thomson Reuters.
Venture capitalists invested $1.4 billion in 174 life sciences
deals, continuing a decline spanning four consecutive quarters.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
Specific Questions relating to this article should be addressed directly to the author.
The Industry Canada and the Canadian Radio-television and Telecommunications Commission Industry Canada published its revised draft ECPR under CASL, which addresses concerns raised after the initial draft.
Technology startups need to know how to raise capital, protect their inventions, access government technology support programs, develop commercialization strategies, and navigate federal and provincial legislation and regulations.